Breaking News Instant updates and real-time market news.

BLUE

Bluebird Bio

$88.99

0.33 (0.37%)

, NVO

Novo Nordisk

$51.50

-0.42 (-0.81%)

08:10
10/09/19
10/09
08:10
10/09/19
08:10

Bluebird Bio, Novo Nordisk enter genome editing research collaboration

Bluebird Bio (BLUE) and Novo Nordisk (NVO) announced that they have entered into a research collaboration to jointly develop next-generation in vivo genome editing treatments for genetic diseases, including haemophilia. During the three-year research collaboration, bluebird and Novo Nordisk will focus on identifying a development gene therapy candidate with the ambition of offering people with haemophilia A a lifetime free of factor replacement therapy. The research collaboration will utilise bluebird bio's proprietary mRNA-based megaTAL technology that has the potential to provide a highly specific and efficient way to silence, edit or insert genetic components. Aligned with Novo Nordisk's haemophilia portfolio, the research collaboration will initially focus on correcting FVIII-clotting factor deficiency, with the potential to explore additional therapeutic targets.

BLUE

Bluebird Bio

$88.99

0.33 (0.37%)

NVO

Novo Nordisk

$51.50

-0.42 (-0.81%)

BLUE Bluebird Bio
$88.99

0.33 (0.37%)

08/12/19
WBLR
08/12/19
DOWNGRADE
WBLR
Market Perform
Bluebird Bio downgraded to Market Perform from Outperform at William Blair
William Blair analyst Raju Prasad downgraded Bluebird Bio to Market Perform from Outperform.
08/12/19
WBLR
08/12/19
DOWNGRADE
WBLR
Market Perform
William Blair downgrades Bluebird Bio, calls Zynteglo launch 'slow mover'
William Blair analyst Raju Prasad downgraded Bluebird Bio to Market Perform from Outperform saying he's taking a conservative view on the company's transition from a development-stage company to a commercial-stage company. Based on the reimbursement model, the analyst believes that the Zynteglo launch is likely to be a "slow mover." Further, Prasad altered his model for bb2121-bb21217 to reflect the increased BCMA competition from both autologous and allogeneic cell therapy approaches that he says are moving faster through the clinic than he initially anticipated.
08/12/19
08/12/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. NetEase (NTES) downgraded to Neutral from Buy at Goldman Sachs with analyst Bill Liu citing the company's Q2 revenues miss, mainly on soft online games growth. 2. Occidental Petroleum (OXY) downgraded to In Line from Outperform at Evercore ISI with analyst Doug Terreson saying the company's "pledge" for greater capital discipline and enhanced corporate governance "proved fleeting" with the significant decline in return on capital employed due to the Anadarko acquisition. 3. Adesto Technologies (IOTS) downgraded to Market Perform from Outperform at Northland with analyst Gus Richard saying the company has $34M of high interest debt and needs $10M to pay an earnout by year end, but he thinks the company is holding off on an offering until it reports a "strong" third quarter that will be boosted by an airpod win at Apple (AAPL). 4. Bluebird Bio (BLUE) downgraded to Market Perform from Outperform at William Blair with analyst Raju Prasad saying he's taking a conservative view on the company's transition from a development-stage company to a commercial-stage company. 5. Cemex (CX) downgraded to Market Perform from Outperform at BBVA. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/30/19
STFL
09/30/19
INITIATION
Target $109
STFL
Hold
Bluebird Bio initiated with a Hold at Stifel
Stifel analyst Benjamin Burnett initiated Bluebird Bio with a Hold rating and a price target of $109. The analyst is concerned that the launch of the company's lead product Zynteglo will be slow, which places a risk on it meeting consensus expectations. Burnett adds that the the bull case on Bluebird Bio is hard to justify because of the tough competition in multiple myeloma.
NVO Novo Nordisk
$51.50

-0.42 (-0.81%)

08/13/19
ROTH
08/13/19
NO CHANGE
Target $31
ROTH
Buy
Roth confident Amarin's Vascepa will be 'well-received' by FDA panel
Roth Capital analyst Yasmeen Rahimi noted that the FDA's upcoming Advisory Committee reviewing the sNDA for Amarin's (AMRN) Vascepa will include ten voting and one non-voting committee members, including five endocrinologists, three cardiologists, a biostatistician, a pharmacoepidemiologist, a consumer representative and a non-voting nephrologist. Given that the American Diabetes Association has included Vascepa for CV risk reduction in its recommended treatment guidelines, and the panel has a majority of endocrinologists, she believes that "the committee is primed for a positive reception of Vascepa," Rahimi tells investors. Additionally, the AdCom Chairperson, Dr. Kenneth Burman, previously voted in favor of Novo Nordisk's (NVO) insulin degludec and insulin degludec/aspart when chairing a prior AdCom. Rahimi reads this as a strong sign that he is receptive to new therapies and as a positive for Vascepa's review, she said. The analyst keeps a Buy rating on Amarin shares with a price target of $31.
08/30/19
JEFF
08/30/19
DOWNGRADE
JEFF
Underperform
Novo Nordisk downgraded to Underperform from Hold at Jefferies
Jefferies analyst Peter Welford downgraded Novo Nordisk to Underperform from Hold while raising his price target for the shares to DKK 300 from DKK 295. The analyst believes the shares at current levels are becoming expensive. Approval of oral semaglutide is imminent in the U.S., but pricing could drive below-average margins, Welford tells investors in a research note.
08/30/19
08/30/19
DOWNGRADE

Fly Intel: Top analyst downgrade
Catch up on today's top analyst downgrades with this list compiled by The Fly: 1. Ulta Beauty (ULTA) downgraded to Neutral from Buy at Citi, to Neutral from Overweight at Piper Jaffray and Atlantic Equities, to Neutral from Outperform at Exane BNP Paribas, to Market Perform from Outperform at Wells Fargo, and to Equal Weight from Overweight at Morgan Stanley. 2. Toronto-Dominion (TD) downgraded to Market Perform from Outperform at BMO Capital with analyst Sohrab Movahedi saying he views the company's Q4 results as a "low-quality meet" and believes the stock's total return potential is now in line with other similarly rated banks. 3. Novo Nordisk (NVO) downgraded to Underperform from Hold at Jefferies with analyst Peter Welford saying he believes the shares at current levels are becoming expensive. 4. UBS (UBS) downgraded to Neutral from Outperform at Exane BNP Paribas. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/17/19
SBSH
09/17/19
UPGRADE
SBSH
Buy
Novo Nordisk upgraded to Buy from Neutral at Citi
Citi analyst Peter Verdult upgraded Novo Nordisk to Buy from Neutral and raised his price target for the shares to DKK 415 from DKK 334. The analyst believes the company's GLP-1 franchise across diabetes, obesity and nonalcoholic steatohepatitis is "burgeoning." His survey of doctors suggests the company's volume penetration in diabetes could reach 25%-35% versus 7% now. Verdult boosted his earnings estimates for Novo through 2024 up to 20% ahead of consensus expectations.

TODAY'S FREE FLY STORIES

SPY

SPDR S&P 500 ETF Trust

$298.89

2.88 (0.97%)

, SPX

S&P 500

$0.00

(0.00%)

20:46
10/15/19
10/15
20:46
10/15/19
20:46
Periodicals
China may retaliate if U.S. Congress passes bill supporting Hong Kong protesters 

Report from Bloomberg.

SPY

SPDR S&P 500 ETF Trust

$298.89

2.88 (0.97%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$29.74

0.59 (2.02%)

, ABT

Abbott

$82.06

2.25 (2.82%)

20:25
10/15/19
10/15
20:25
10/15/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BAC

Bank of America

$29.74

0.59 (2.02%)

ABT

Abbott

$82.06

2.25 (2.82%)

USB

U.S. Bancorp

$53.73

0.47 (0.88%)

PNC

PNC Financial

$141.86

1.38 (0.98%)

BK

BNY Mellon

$44.37

0.47 (1.07%)

ALLY

Ally Financial

$32.03

0.68 (2.17%)

CMA

Comerica

$67.01

1.765 (2.71%)

FHN

First Horizon

$16.13

0.22 (1.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 27

    Oct

  • 07

    Nov

  • 12

    Nov

RIO

Rio Tinto

$51.40

-0.43 (-0.83%)

20:17
10/15/19
10/15
20:17
10/15/19
20:17
Hot Stocks
Rio Tinto reports Q3 Pilbara iron ore output 87.3M tons, up 6% from last year »

Reports Q3 Pilbara iron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNTX

Gentex

$26.98

0.65 (2.47%)

20:16
10/15/19
10/15
20:16
10/15/19
20:16
Initiation
Gentex initiated  »

Gentex initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 04

    Nov

VNE

Veoneer

$16.11

0.82 (5.36%)

20:16
10/15/19
10/15
20:16
10/15/19
20:16
Initiation
Veoneer initiated  »

Veoneer initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

VC

Visteon

$82.45

0.63 (0.77%)

20:15
10/15/19
10/15
20:15
10/15/19
20:15
Initiation
Visteon initiated  »

Visteon initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

DLPH

Delphi Technologies

$14.37

0.45 (3.23%)

20:14
10/15/19
10/15
20:14
10/15/19
20:14
Initiation
Delphi Technologies initiated  »

Delphi Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

BWA

BorgWarner

$37.74

0.68 (1.83%)

20:13
10/15/19
10/15
20:13
10/15/19
20:13
Initiation
BorgWarner initiated  »

BorgWarner initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

LEA

Lear

$121.75

3.94 (3.34%)

20:13
10/15/19
10/15
20:13
10/15/19
20:13
Initiation
Lear initiated  »

Lear initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 04

    Nov

  • 10

    Dec

  • 11

    Dec

DFIN

Donnelley Financial Solutions

$10.54

0.035 (0.33%)

20:12
10/15/19
10/15
20:12
10/15/19
20:12
Initiation
Donnelley Financial Solutions initiated  »

Donnelley Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$132.84

2.17 (1.66%)

, TEVA

Teva

$6.96

0.22 (3.26%)

19:17
10/15/19
10/15
19:17
10/15/19
19:17
Periodicals
As part of proposed settlement, Teva offers $15B of free drugs, Bloomberg says »

The report also notes…

JNJ

Johnson & Johnson

$132.84

2.17 (1.66%)

TEVA

Teva

$6.96

0.22 (3.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 07

    Nov

WAFD

Washington Federal

$36.81

0.15 (0.41%)

19:04
10/15/19
10/15
19:04
10/15/19
19:04
Earnings
Washington Federal reports Q4 EPS 66c, consensus 65c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

INGR

Ingredion

$81.17

0.94 (1.17%)

19:01
10/15/19
10/15
19:01
10/15/19
19:01
Hot Stocks
Ingredion discloses malware affecting certain data centers »

Ingredion issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$298.89

2.88 (0.97%)

19:01
10/15/19
10/15
19:01
10/15/19
19:01
Periodicals
Pelosi holds off on House vote over impeachment inquiry, Politico says »

House Speaker Nancy…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$298.89

2.88 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBR

Petrobras

$14.40

0.02 (0.14%)

18:59
10/15/19
10/15
18:59
10/15/19
18:59
Hot Stocks
Petrobras signs charter contracts for two FPSO platforms »

Petrobras announced that …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

SNBR

Sleep Number

$46.69

0.48 (1.04%)

, UAL

United Airlines

$87.90

0.9 (1.03%)

18:58
10/15/19
10/15
18:58
10/15/19
18:58
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Sleep…

SNBR

Sleep Number

$46.69

0.48 (1.04%)

UAL

United Airlines

$87.90

0.9 (1.03%)

MCK

McKesson

$138.17

4.01 (2.99%)

ABC

AmerisourceBergen

$83.18

1.6 (1.96%)

CAH

Cardinal Health

$47.93

1.16 (2.48%)

FULT

Fulton Financial

$15.90

0.19 (1.21%)

ETN

Eaton

$82.16

1.29 (1.60%)

SFIX

Stitch Fix

$20.83

-0.38 (-1.79%)

MGM

MGM Resorts

$27.87

-0.1 (-0.36%)

JBHT

J.B. Hunt

$111.65

1.985 (1.81%)

IBKR

Interactive Brokers

$47.43

0.26 (0.55%)

RYTM

Rhythm Pharmaceuticals

$20.90

0.52 (2.55%)

PRQR

ProQR Therapeutics

$6.21

-0.09 (-1.43%)

NTRA

Natera

$39.21

1.01 (2.64%)

PRNB

Principia Biopharma

$29.88

0.7 (2.40%)

X

U.S. Steel

$11.43

0.27 (2.42%)

ARCE

Arco Platform

$48.15

0.75 (1.58%)

TW

Tradeweb Markets

$39.79

-0.14 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 18

    Oct

KKR

KKR

$26.79

0.67 (2.57%)

, DB

Deutsche Bank

$7.79

0.235 (3.11%)

18:21
10/15/19
10/15
18:21
10/15/19
18:21
Periodicals
KKR, partners cancel Latitude Financial IPO, Reuters reports »

KKR (KKR) and its…

KKR

KKR

$26.79

0.67 (2.57%)

DB

Deutsche Bank

$7.79

0.235 (3.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 29

    Oct

  • 04

    Nov

TW

Tradeweb Markets

$39.79

-0.14 (-0.35%)

18:20
10/15/19
10/15
18:20
10/15/19
18:20
Hot Stocks
Breaking Hot Stocks news story on Tradeweb Markets »

Tradeweb Markets sees Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 18

    Oct

TW

Tradeweb Markets

$39.79

-0.14 (-0.35%)

18:17
10/15/19
10/15
18:17
10/15/19
18:17
Syndicate
Tradeweb Markets files to sell 14.8M shares of Class A common stock »

Refinitiv will continue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 18

    Oct

TW

Tradeweb Markets

$39.79

-0.14 (-0.35%)

18:16
10/15/19
10/15
18:16
10/15/19
18:16
Earnings
Tradeweb Markets sees Q3 adjusted EPS 27c, consensus 25c »

Sees Q3 revenue $200.98M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 18

    Oct

EDIT

Editas Medicine

$20.30

0.48 (2.42%)

18:15
10/15/19
10/15
18:15
10/15/19
18:15
Hot Stocks
Editas Medicine, AskBio enter research collaboration over in vivo delivery »

Editas Medicine and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$114.78

2.43 (2.16%)

18:03
10/15/19
10/15
18:03
10/15/19
18:03
Periodicals
NV regulators want to ban Steve Wynn from NV casino industry, Reuters says »

The Nevada Gaming Control…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFIX

Stitch Fix

$20.83

-0.38 (-1.79%)

18:00
10/15/19
10/15
18:00
10/15/19
18:00
Hot Stocks
Stitch Fix director buys 150K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

NTRA

Natera

$39.21

1.01 (2.64%)

17:48
10/15/19
10/15
17:48
10/15/19
17:48
Syndicate
Natera files to sell $175M of common stock »

J.P. Morgan, Morgan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQST

Aquestive Therapeutics

$3.36

0.2 (6.33%)

17:45
10/15/19
10/15
17:45
10/15/19
17:45
Earnings
Aquestive backs FY19 revenue $38M-$45M, consensus $42.82M »

Aquestive Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.